Drugs / GLPG3667
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT05335447 | Apr → Jun 2022 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT05272683 | Feb → Apr 2022 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT04976270 | Jul 2021 → Jan 2022 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT04736927 | Jan → Feb 2021 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT04594928 | Oct 2020 → May 2021 | psoriasis | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT04097938 | Sep 2019 → Mar 2020 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT05856448 | Jun 2023 → Oct 2025 | systemic lupus erythematosus | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 2 | NCT05695950 | Feb 2023 → Oct 2025 | dermatomyositis | Lakefront Biotherapeutics NV | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-12-18 | Lakefront Biotherapeutics NV | Results Galapagos Announces Topline Results from Two Phase 3-Enabling Studies with Selective TYK2 Inhibitor GLPG3667 in Dermatomyositis and Systemic Lupus Erythematosus lakefrontbio.com ↗
GLPG3667 met primary endpoint in dermatomyositis study, demonstrating a statistically significant clinical benefit and meaningful improvements on secondary measures of disease activity compared to placebo |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-12-18 | Lakefront Biotherapeutics NV | Galapagos Announces Topline Results from Two Phase 3-Enabling Studies with Selective TYK2 Inhibitor GLPG3667 in Dermatomyositis and Systemic Lupus Erythematosus lakefrontbio.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLPG3667 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05856448 ↗ |
| Action | Inhibit | “Discovery of GLPG3667, a Selective ATP Competitive Tyrosine Kinase 2 Inhibitor” PMID 38805213 ↗ May 2024 |
| Modality | Small molecule | “Discovery of GLPG3667, a Selective ATP Competitive Tyrosine Kinase 2 Inhibitor” PMID 38805213 ↗ May 2024 |
| Route | Oral | “after oral single ascending doses (SAD) of GLPG3667” NCT04097938 ↗ |
| Target | TYK2 | “TYK2 selectivity was confirmed in peripheral blood mononuclear cells and whole blood assays.” PMID 38805213 ↗ May 2024 |